Evolent Health, Inc. (NYSE:EVH) Director Diane Holder Acquires 2,735 Shares of Stock

Evolent Health, Inc. (NYSE:EVH) Director Diane Holder acquired 2,735 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The stock was purchased at an average price of $9.33 per share, with a total value of $25,517.55. Following the completion of the acquisition, the director now owns 70,584 shares in the company, valued at $658,548.72. The trade was a 4.03 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Evolent Health Stock Up 0.7 %

Shares of NYSE EVH opened at $9.06 on Tuesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market cap of $1.06 billion, a P/E ratio of -11.04 and a beta of 1.49. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $34.51. The firm has a 50-day simple moving average of $10.33 and a two-hundred day simple moving average of $17.45.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). The firm had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. Research analysts anticipate that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

EVH has been the subject of a number of research reports. BTIG Research decreased their target price on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, December 3rd. Royal Bank of Canada decreased their target price on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, January 14th. Stephens decreased their target price on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. Piper Sandler restated an “overweight” rating and issued a $16.00 price objective (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Finally, Oppenheimer reduced their price objective on Evolent Health from $28.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, January 24th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $17.71.

Institutional Trading of Evolent Health

Institutional investors have recently added to or reduced their stakes in the company. Covestor Ltd increased its position in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after acquiring an additional 826 shares during the period. Summit Creek Advisors LLC increased its position in shares of Evolent Health by 0.8% during the fourth quarter. Summit Creek Advisors LLC now owns 202,114 shares of the technology company’s stock worth $2,274,000 after acquiring an additional 1,636 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Evolent Health during the fourth quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its position in shares of Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after acquiring an additional 2,358 shares during the period. Finally, Johnson Investment Counsel Inc. increased its position in shares of Evolent Health by 28.0% during the fourth quarter. Johnson Investment Counsel Inc. now owns 11,607 shares of the technology company’s stock worth $131,000 after acquiring an additional 2,542 shares during the period.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.